Correction: Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-15-0185
Full Text
Abstract

Available in full text

Date
Authors

Unknown

Publisher

American Association for Cancer Research (AACR)


Related search